Why is "Cytarabine" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-07-16 07:57:33
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Cytarabine entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-16 and was most recently seen on 2026-07-16.
Wikipedia Overview
Cytarabine, also known as cytosine arabinoside (ara-C), is a chemotherapy medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma. It is given by injection into a vein, under the skin, or into the cerebrospinal fluid. There is a liposomal formulation for which there is tentative evidence of better outcomes in lymphoma involving the meninges.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Fixed-duration cytarabine consolidation improves relapse-free survival over indefinite AZA–VEN in younger AML - Nature
-
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia - Wiley Online Library
-
Annamycin Plus Cytarabine Generates Higher Complete Remission Rates vs Control in R/R AML - OncLive
-
Cytarabine: Mechanism of Action, Dose, Administration, Clinical Uses, and Side Effects - Oncodaily
-
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients | Blood Cancer Journal - Nature
-
Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML - MedPage Today
-
ASH 2025: Refining Chemotherapy and Biomarker-Adapted Strategies in AML - cancertherapyadvisor.com
-
Annamycin Plus Cytarabine Delivers Promising Response Rates in R/R AML - OncLive
-
Right Chemo, Wrong Route: Risks of Intrathecal Administration of Chemotherapy - ASCO Publications
-
Synergistic Anti‐Lung Cancer Effects of Cytarabine and a NCBI‐Registered Streptococcus via Modulation of Apoptotic and Survival Pathways - Wiley Online Library
-
Moleculin reports interim results from MIRACLE trial in r/r AML patients - Clinical Trials Arena
-
Superiority of high-dose cytarabine–based mobilisation over cyclophosphamide or plerixafor in primary CNS lymphoma - SpringerMedizin.de
-
Intermediate-Dose Cytarabine as Postinduction AML Therapy - NEJM Evidence
-
Phase III MATRix/IELSG43 trial: HCT–ASCT vs non-myeloablative R-DeVIC consolidation in PCNSL - Lymphoma Hub
-
Annamycin shows encouraging early results in Phase 2/3 AML clinical trial - Rare Cancer News
-
Nathan Punwani: Continuous IV and Bolus Cytarabine as Two Different Drugs in AML - Oncodaily
-
Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms - Nature
-
Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine - Nature
-
Sequential CLAGE-Ven (cladribine, cytarabine, etoposide, and venetoclax) with reduced-intensity conditioning improves outcomes in patients with refractory acute myeloid leukemia: a prospective phase II study - Nature
-
Mechanism of cytarabine-induced neurotoxicity - Nature
-
Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis - Nature
-
IC in combination with quizartinib or midostaurin for ND FLT3-ITD AML: A multicenter cohort study - aml-hub.com
-
Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia - Nature
-
CLAD + LDAC + Ven or Aza + Ven for older or unfit patients with ND AML: Phase II results - aml-hub.com
-
Intake of oligoelements with cytarabine or etoposide alters dopamine levels and oxidative damage in rat brain - Nature
-
Chidamide and cytarabine synergistically treat acute myeloid leukemia: inhibiting ribosome biogenesis via the MYC-RRP9 pathway - Nature
-
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial - Nature
-
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia - NEJM
-
Concanavalin A staining: a potential biomarker to predict cytarabine sensitivity in acute myeloid leukemia - Frontiers
-
Uncertainties Surround Optimal Dosing of Cytarabine in AML - cancertherapyadvisor.com
-
Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis - Nature
-
Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia - Nature
-
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia | Blood Cancer Journal - Nature
-
Cytarabine Dose for Acute Myeloid Leukemia - NEJM
-
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase - National Institutes of Health (NIH) | (.gov)
-
Metformin and chloroquine enhanced the efficacy of cytarabine in acute lymphoblastic leukemia cell lines: a drug repositioning approach - Nature
-
The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia - Nature
-
Annamycin Plus Cytarabine Drive Potential OS Benefit in Acute Myeloid Leukemia - OncLive
-
Comparison of subcutaneous injection versus intravenous infusion of cytarabine for induction therapy in adult acute myeloid leukemia - Nature
-
Mechanisms of chemotherapy failure in refractory/relapsed acute myeloid leukemia: the role of cytarabine resistance and mitochondrial metabolism | Cell Death & Disease - Nature
-
Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma - Nature
-
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia - Nature
-
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome - Nature
-
Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial - Wiley & Sons
-
Structural insights into mutagenicity of anticancer nucleoside analog cytarabine during replication by DNA polymerase η - Nature
-
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial - Nature
-
Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis - Nature
-
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network | Leukemia - Nature
-
Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro - Nature
-
Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203 - Nature
-
First Patient Dosed With Annamycin and Cytarabine in Phase 3 AML Trial - Cure Today
-
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia - Nature
-
Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach | Leukemia - Nature
-
Daiichi Sankyo’s Vanflyta secures Korean approval for FLT3-ITD–positive AML - Korea Biomedical Review
-
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies - Nature
-
FDA Approves Expanded Indication of Daunorubicin/Cytarabine to Include Children With AML - CancerNetwork
-
FIL_V-RBAC trial: RBAC + venetoclax in older patients with high-risk MCL - Lymphoma Hub
-
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML - Nature
-
Venetoclax Plus Low-Dose Cytarabine Improves Survival and Remission in Patients With Chemotherapy-Ineligible AML - ashpublications.org
-
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial - The Lancet
-
Pediatric AML: Low-dose induction is noninferior to standard-dose chemotherapy - Vera Health
-
Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs - Wiley & Sons
-
Diffuse Alveolar Hemorrhage in the Setting of Cytarabine Therapy in a Critically Ill Patient - Cureus
-
FDA Completes End-of-Phase 2 Meeting for Annamycin Plus Cytarabine in AML - OncLive
-
Palmar–Plantar Rash with Cytarabine Therapy - NEJM
-
Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia - Nature
-
Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells - Nature
-
Cytarabine and Daunorubicin Combination Appears Safe and Effective in Higher-Risk MDS, CML - Hematology Advisor
-
Flow chart of acute leukemia cases. - PLOS
-
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study - Nature
-
A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment - Wiley & Sons
-
Long-Term Follow-up of High-Dose Cytarabine and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma - The ASCO Post
-
UF-developed genetic score improves outcomes by personalizing leukemia therapy - UF Health
-
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis - Haematologica
-
Cytarabine in Young Adults With AML: Subcutaneous Injection Noninferior to IV Infusion - Oncology Nurse Advisor
-
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial - The Lancet
-
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial - The Lancet
-
Annamycin Earns European Orphan Drug Designation in Acute Myeloid Leukemia - CancerNetwork
-
RETRACTED ARTICLE: Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4 - Nature
-
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study - The Lancet
-
Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia - Frontiers
-
High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia - Nature
-
Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma - Nature
-
Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells - ScienceDirect.com
-
Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis - Wiley Online Library
-
Ziftomenib With 7+3 Shows Early Promise in Newly Diagnosed NPM1-Mutated/KMT2A-Rearranged AML - OncLive
-
Venetoclax, Cladribine, Idarubicin, Cytarabine Regimen Evaluated in AML, High-Risk MDS - Docwire News
-
A Case Report of Cytarabine-Induced Red Ear Syndrome - Cureus
-
Brentuximab vedotin, dexamethasone, high-dose cytarabine, and cisplatin for R/R cHL - Lymphoma Hub
-
Is age just a number? Intensive therapy for core-binding factor acute myeloid leukemia in older adults - Haematologica
-
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML - Leukemia - Nature
-
Mitoxantrone, etoposide, and cytarabine versus mitoxantrone and high-dose cytarabine for R/R AML - aml-hub.com
-
VALDAC: A prospective study of venetoclax and low-dose cytarabine for MRD and oligoblastic relapse in AML - aml-hub.com
-
Study Reaffirms the Use of Cytarabine in Younger Patients With Mantle Cell Lymphoma - cancertherapyadvisor.com
-
High‐dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years - Wiley & Sons
-
Clinical Efficacy of Decitabine in Combination With Standard-dose Cytarabine, Aclarubicin Hydrochloride, and Granulocyte Colony-stimulating Factor in the Treatment of Young Patients With Newly Diagnosed Acute Myeloid Leukemia - Oncology Nurse Advisor
-
CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1 - Nature
-
Core binding factor acute myelogenous leukemia-2021 treatment algorithm | Blood Cancer Journal - Nature
-
Case report: Dysphonia associated with high-dose cytarabine therapy - Frontiers
-
Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect - Wiley Online Library
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.